ALT5 Sigma (NASDAQ:ALTS) Trading 3.2% Higher – Should You Buy?

ALT5 Sigma Corporation (NASDAQ:ALTS) shares were up 3.2% during trading on Friday . The company traded as high as $3.01 and last traded at $2.87. Approximately 8,414,030 shares were traded during trading, a decline of 11% from the average daily volume of 9,437,154 shares. The stock had previously closed at $2.78.

Wall Street Analyst Weigh In

ALTS has been the subject of a number of recent analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of ALT5 Sigma in a report on Saturday, September 27th. Wall Street Zen cut ALT5 Sigma from a “hold” rating to a “strong sell” rating in a research note on Saturday, August 16th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, ALT5 Sigma presently has a consensus rating of “Sell”.

ALT5 Sigma Stock Up 3.2%

The firm’s 50 day simple moving average is $5.29 and its two-hundred day simple moving average is $6.31. The company has a quick ratio of 0.88, a current ratio of 0.88 and a debt-to-equity ratio of 1.45.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Evernest Financial Advisors LLC acquired a new stake in ALT5 Sigma in the second quarter valued at approximately $87,000. Bridgeway Capital Management LLC lifted its holdings in shares of ALT5 Sigma by 9.4% in the 2nd quarter. Bridgeway Capital Management LLC now owns 19,339 shares of the company’s stock worth $140,000 after purchasing an additional 1,661 shares in the last quarter. Jane Street Group LLC acquired a new stake in ALT5 Sigma in the 2nd quarter valued at $380,000. Finally, Geode Capital Management LLC increased its stake in ALT5 Sigma by 27.6% during the 2nd quarter. Geode Capital Management LLC now owns 194,813 shares of the company’s stock valued at $1,412,000 after purchasing an additional 42,157 shares in the last quarter. Institutional investors own 6.27% of the company’s stock.

About ALT5 Sigma

ALT5 Sigma Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments.